Bull Case

Bausch + Lomb sustains premium eye-care demand and launches new products, lifting revenue and margins faster than Alcon and Cooper.

Operating profit margin expands as manufacturing efficiencies and mix shift toward higher-margin surgical and consumer franchises offset legacy pressure.

Debt reduction and improved cash conversion lower leverage from elevated levels, easing interest burden relative to highly levered peers.

Execution on portfolio simplification and selective pricing supports steadier growth, while peers with narrower product breadth face more concentration risk.

Base Case

Core eye-care demand remains resilient, but modest product growth and competitive pricing keep revenue expansion broadly in line with Alcon and Cooper.

Operating margins hold near current levels as mix benefits and cost actions offset ongoing investment needs and integration complexity.

High leverage persists, limiting financial flexibility and keeping cash flow more constrained than less levered peers despite stable operating performance.

Portfolio breadth supports stability, yet slower deleveraging versus peers prevents a stronger forward rerating in the most likely outcome.

Bear Case

Slower procedure volumes and weaker consumer demand pressure revenue, while peers with stronger balance sheets absorb the downturn more easily.

Pricing pressure and product mix deterioration compress margins, reversing recent operating gains and widening the gap versus Alcon and Cooper.

High leverage and thin interest coverage constrain refinancing options, raising financial risk if cash generation softens further.

Execution setbacks or litigation-related costs absorb cash, leaving BHC more vulnerable than better-capitalized peers in a prolonged downturn.

Overall Score

BHC’s forward path is supported by resilient eye-care demand and margin stability, but elevated leverage and slower deleveraging versus peers cap overall strength.